Periodic/Sector reports
China Healthcare: Bi-Weekly: China's 15th Five-Year Pharma Plan Signals Long-Term Support For Biopharma And AI Drug R&D
MARKET WEIGHT (Maintained)
Analyst
Analyst
Highlights
- The HSHCI rose significantly by 8.5% during 16-30 September, supported by the strong healthcare market sentiment in both China and the overseas market. Akeso, Insilico, XtalPi, CSPC, WuXi Bio, and WuXi AppTec were the major outperformers.
- China's 15th Five-Year Plan for the pharmaceutical industry strikes a supportive tone for the long-term development of the broader biopharmaceutical sector. It also champions AI-enabled drug discovery and development – an area that has drawn rising investor interest in recent years.
- Maintain MARKET WEIGHT.
Bi-Weekly Recap
- Ali Health (241 HK/BUY/Target: HK$4.00) lowered its FY27 revenue growth target from 10-15% to 7-10% yoy, while keeping adjusted net profit guidance unchanged at Rmb1.9b-2.3b. This reflects proactive optimisation of product-price subsidies, with savings redeployed into B2C+O2O supply chain integration. Drug sales remain the primary growth engine, expanding at a high double-digit rate in FY27, while non-drug categories grow at a low single-digit rate. Despite near-term moderation in revenue and earnings, we see structural opportunities from sustained innovative drug momentum, expanding AI adoption, and deepening Alibaba ecosystem synergies.
Major Industry News
- China released the Pharma Industry 15th Five-Year Plan on 18 September. The plan sets 2030 targets: Five domestic drugs with global annual sales above US$1b; first-in-class (FIC) drugs to reach over 25% of the global total; innovative-drug industry scale to grow over 20% per year; and 50 pharmaceutical manufacturers with annual revenue above Rmb10b. It plans to set up a full-lifecycle drug price formation mechanism to support globalisation of China pharmaceutical industry. It highlights four priority biologics areas: Antibodies/recombinant proteins, next-generation conjugates, cell and gene therapy, and new vaccines. The plan also promotes AI-driven pharmaceutical R&D, and precision diagnosis and treatment of cancers, major chronic diseases and infectious diseases.
Highlights
- The HSHCI rose significantly by 8.5% during 16-30 September, supported by the strong healthcare market sentiment in both China and the overseas market. Akeso, Insilico, XtalPi, CSPC, WuXi Bio, and WuXi AppTec were the major outperformers.
- China's 15th Five-Year Plan for the pharmaceutical industry strikes a supportive tone for the long-term development of the broader biopharmaceutical sector. It also champions AI-enabled drug discovery and development – an area that has drawn rising investor interest in recent years.
- Maintain MARKET WEIGHT.
Bi-Weekly Recap
- Ali Health (241 HK/BUY/Target: HK$4.00) lowered its FY27 revenue growth target from 10-15% to 7-10% yoy, while keeping adjusted net profit guidance unchanged at Rmb1.9b-2.3b. This reflects proactive optimisation of product-price subsidies, with savings redeployed into B2C+O2O supply chain integration. Drug sales remain the primary growth engine, expanding at a high double-digit rate in FY27, while non-drug categories grow at a low single-digit rate. Despite near-term moderation in revenue and earnings, we see structural opportunities from sustained innovative drug momentum, expanding AI adoption, and deepening Alibaba ecosystem synergies.
Major Industry News
- China released the Pharma Industry 15th Five-Year Plan on 18 September. The plan sets 2030 targets: Five domestic drugs with global annual sales above US$1b; first-in-class (FIC) drugs to reach over 25% of the global total; innovative-drug industry scale to grow over 20% per year; and 50 pharmaceutical manufacturers with annual revenue above Rmb10b. It plans to set up a full-lifecycle drug price formation mechanism to support globalisation of China pharmaceutical industry. It highlights four priority biologics areas: Antibodies/recombinant proteins, next-generation conjugates, cell and gene therapy, and new vaccines. The plan also promotes AI-driven pharmaceutical R&D, and precision diagnosis and treatment of cancers, major chronic diseases and infectious diseases.
MARKET WEIGHT (Maintained)
Analyst
Analyst
IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS
This report is provided subject to, and must be read together with, the full Disclosures / Disclaimers available at this link, which are incorporated by reference into this report. In particular, this report is intended for general circulation and informational purposes only and does not constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report. By accessing, receiving or using this report, you acknowledge that you have read, understood and agreed to be bound by the Disclosures / Disclaimers, as may be amended, supplemented or updated from time to time.
Related articles
Periodic/Sector reports
17 Sept 2026
China Healthcare - Bi-Weekly: Strengthening Innovation To Sustain Growth
Periodic/Sector reports
8 Sept 2026
China Healthcare: Innovation And Globalisation: The Twin Engines For Growth
Periodic/Sector reports
17 Sept 2026
Hong Kong Property: Takeaways From 2026 Policy Address And Hong Kong’s Five-Year Plan
Our latest research
Periodic/Sector reports
2 Oct 2026
Macau Gaming: Sep 26’s GGR Misses Consensus Estimates By 3%
Periodic/Sector reports
30 Sept 2026
China Property: First Central Mortgage Interest Subsidy From 1 Oct 26; Tier 1 Land Supply Up 12% mom In Sep 26
Periodic/Sector reports
30 Sept 2026